Colgate-Palmolive delivered a solid fourth quarter and a transformative 2024, underscoring a strategy focused on brand health, innovation, and higher advertising intensity to strengthen household penetration. In 2024, net sales reached $4.9455 billion in Q4 terms, with full-year revenue near $20 billion—one year ahead of the company’s strategic plan. The company achieved a resilient gross margin of 60.3% in Q4, driven by mix benefits from Hill’s and Oral Care, and margin expansion despite meaningful FX headwinds and higher advertising spend (up 15% in 2024). Operating margin stood at about 21.5% in the quarter, with net Income of $739 million and EPS of $0.90 for the period. Management reiterated a disciplined plan for 2025, emphasizing organic growth at the top end of the 3-5% target, and a shift toward volume-driven growth, supported by a 2.0 evolution of Revenue Growth Management (RGM), ongoing innovation, and a strong investment in capabilities (data, analytics, AI). Management signaled that 2025 will feature continued margin discipline and flexibility to reallocate resources toward growth initiatives, while acknowledging FX as a meaningful headwind for the year. The firm also highlighted the Total relaunch as a meaningful catalyst for category growth and improved margin mix across geographies, with a broader rollout planned after a successful Latin America launch. The 2030 strategy has begun to take shape, emphasizing consistency, incremental innovation, and greater use of data/AI in decision-making. Investors should monitor FX developments (notably LatAm headwinds and potential tariff impacts), Hill’s margin progression, the pace of North American price/volume normalization, and Europe’s ongoing market-share momentum. Overall, Colgate remains positioned to deliver mid-term earnings growth through a combination of top-line expansion, margin improvement, and robust cash generation.